➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Dow
Johnson and Johnson
McKesson
Moodys

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Claims for Patent: 10,118,965

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 10,118,965
Title:Compositions and methods related to anti-EGFR antibody drug conjugates
Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-epidermal growth factor receptor (\"EGFR\") antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the drug; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
Inventor(s): Kim; Yong Zu (Daejeon, KR), Park; Yun Hee (Daejeon, KR), Choi; Hyo Jung (Daejeon, KR), Jung; Ji Eun (Daejeon, KR), Ryu; Jeong Hee (Daejeon, KR), Song; Ho Young (Daejeon, KR), Chae; Jeiwook (Daejeon, KR), Chung; Chul-Woong (Daejeon, KR)
Assignee: LegoChem Biosciences, Inc. (Daejeon, KR)
Application Number:15/276,231
Patent Claims:1. An antibody drug conjugate, having the structure of Formula I: ##STR00028## wherein: G is a glucuronic acid moiety or ##STR00029## wherein R3 is hydrogen or a carboxyl protecting group; and each R.sub.4 is independently hydrogen or a hydroxyl protecting group; A represents an anti-EGFR antibody; B represents an active agent; W is --C(O)--, --C(O)NR'--, --C(O)O--, --S(O).sub.2NR'--, --P(O)R''NR'--, --S(O)NR'--, or --PO.sub.2NR'--, in each case where the C(O), S, or P is directly bound to the phenyl ring, and R' and R'' are each independently hydrogen, (C.sub.1-C.sub.8)alkyl, (C.sub.3-C.sub.8)cycloalkyl, (C.sub.1-C.sub.8)alkoxy, (C.sub.1-C.sub.8)alkylthio, mono- or di-(C.sub.1-C.sub.8)alkylamino, (C.sub.3-C.sub.20)heteroaryl, or (C.sub.6-C.sub.20)aryl; each Z independently represents hydrogen, (C.sub.1-C.sub.8)alkyl, halogen, cyano, or nitro; n is an integer from 1 to 3; L comprises an alkylene chain of 3 to 50 atoms that covalently links A to W, wherein the chain further comprises an oxime and either: (a) the oxygen atom of the oxime is substituted with a group that covalently links the oxime to W; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to A; or (b) the carbon atom of the oxime is substituted with a group that covalently links the oxime to W; and the oxygen atom of the oxime is substituted with a group that covalently links the oxime to A; R.sub.1 and R.sub.2 are each independently hydrogen, (C.sub.1-C.sub.8)alkyl, or (C.sub.3-C.sub.8)cycloalkyl, or R.sub.1 and R.sub.2 taken together with the carbon atom to which they are attached form a (C.sub.3-C.sub.8)cycloalkyl ring; and the moieties connecting A and B, taken together, form the linker.

2. The antibody-drug conjugate of claim 1, wherein W represents --C(O)NR'--, wherein C(O) is bonded to the phenyl ring and NR' is bonded to L.

3. The antibody-drug conjugate of claim 1, wherein the linker comprises at least one isoprenyl unit, represented by ##STR00030##

4. The antibody-drug conjugate of claim 3, wherein the isoprenyl unit covalently links the oxime to the antibody.

5. The antibody-drug conjugate of claim 4, wherein the linker comprises: ##STR00031##

6. The antibody-drug conjugate of claim 1, wherein the linker comprises at least one polyethylene glycol unit, represented by ##STR00032##

7. The antibody-drug conjugate of claim 6, wherein the linker comprises an oxime, and the at least one polyethylene glycol unit covalently links the oxime to the active agent.

8. The antibody-drug conjugate of claim 2, wherein the linker comprises a connection unit represented by --(CH.sub.2).sub.r(V(CH.sub.2).sub.p).sub.q--, wherein: r is an integer of 1 to 10; p is an integer of 0 to 10; q is an integer of 1 to 10; V is a single bond, --O--, --S--, --NR.sub.21--, --C(O)NR.sub.22--, --NR.sub.23C(O)--, --NR.sub.24SO.sub.2--, or --SO.sub.2NR.sub.25--; and R.sub.21 to R.sub.25 are each independently hydrogen, (C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkyl(C.sub.6-C.sub.20)aryl, or (C.sub.1-C.sub.6)alkyl(C.sub.3-C.sub.20)heteroaryl.

9. The antibody-drug conjugate of claim 1, wherein the linker comprises a connection unit represented by (CH.sub.2CH.sub.2X).sub.w--, wherein: X represents --O--, (C.sub.1-C.sub.8)alkylene, or --NR.sub.21--; R.sub.21 represents hydrogen, (C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkyl(C.sub.6-C.sub.20)aryl, or (C.sub.1-C.sub.6)alkyl(C.sub.3-C.sub.20)heteroaryl; and w is an integer of 1 to 10.

10. The antibody-drug conjugate of claim 1, wherein the linker comprises a linking moiety formed by a 1,3-dipolar cycloaddition reaction, hetero-Diels-Alder reaction, nucleophilic substitution reaction, non-aldol type carbonyl reaction, addition to carbon-carbon multiple bond, oxidation reaction, or click reaction.

11. The antibody-drug conjugate of claim 10, wherein the linking moiety is represented by any one of Formulas A, B, C, or D: ##STR00033## wherein: L.sub.1 is a single bond or alkylene having 1 to 30 carbon atoms; R.sub.11 is hydrogen or alkyl having 1 to 10 carbon atoms; and L.sub.2 is alkylene having 1 to 30 carbon atoms.

12. The antibody-drug conjugate of claim 11, wherein: the linker comprises ##STR00034## V is a single bond, --O--, --S--, --NR.sub.21--, --C(O)NR.sub.22--, --NR.sub.23C(O)--, --NR.sub.24SO.sub.2--, or --SO.sub.2NR.sub.25--; R.sub.21 to R.sub.25 are each independently hydrogen, (C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkyl(C.sub.6-C.sub.20)aryl, or (C.sub.1-C.sub.6)alkyl(C.sub.3-C.sub.20)heteroaryl; r is an integer of 1 to 10; p is an integer of 0 to 10; q is an integer of 1 to 10; and L.sub.1 is a single bond.

13. The antibody-drug conjugate of claim 1, comprising the structure of Formula III: ##STR00035## wherein A represents the antibody; and B represents the active agent.

14. The antibody-drug conjugate of claim 1, wherein the linker is covalently bound to the antibody by a thioether bond, and the thioether bond comprises a sulfur atom of a cysteine of the antibody.

15. The antibody-drug conjugate of claim 1, wherein the antibody is a monoclonal antibody, polyclonal antibody, antibody fragment, Fab, Fab', Fab'-SH, F(ab').sub.2, Fv, single chain Fv ("scFv"), diabody, linear antibody, bispecific antibody, multispecific antibody, chimeric antibody, humanized antibody, human antibody, or fusion protein comprising the antigen-binding portion of an antibody.

16. The antibody-drug conjugate of claim 1, wherein the antibody can specifically bind an extracellular epitope on EGFR.

17. The antibody-drug conjugate of claim 1, wherein the active agent is a chemotherapeutic agent or a toxin.

18. The antibody-drug conjugate of claim 1, wherein the active agent is selected from: (a) erlotinib, bortezomib, fulvestrant, sutent, letrozole, imatinib mesylate, PTK787/ZK 222584, oxaliplatin, 5-fluorouracil, leucovorin, rapamycin, lapatinib, lonafarnib, sorafenib, gefitinib, AG1478, AG1571, thiotepa, cyclophosphamide, busulfan, improsulfan, piposulfan, benzodopa, carboquone, meturedopa, uredopa, ethylenimine, altretamine, triethylenemelamine, trietylenephosphoramide, triethiylenethiophosphoramide, trimethylolomelamine, bullatacin, bullatacinone, camptothecin, topotecan, bryostatin, callystatin, CC-1065, adozelesin, carzelesin, bizelesin, cryptophycin 1, cryptophycin 8,dolastatin, duocarmycin, KW-2189, CB1-TM1, eleutherobin, pancratistatin, sarcodictyin, spongistatin, chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimnustine, calicheamicin, calicheamicin gamma 1, calicheamicin omega 1, dynemicin, dynemicin A, clodronate, esperamicin, neocarzinostatin chromophore, aclacinomysins, actinomycin, antrmycin, azaserine, bleomycins, cactinomycin, carabicin, carninomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubucin, 6-diazo-5-oxo-L-norleucine, doxorubicin, morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubucin, liposomal doxorubicin, deoxydoxorubicin, epirubicin, esorubicin, marcellomycin, mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptomigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, 5-fluorouracil, denopterin, methotrexate, pteropterin, trimetrexate, fludarabine, 6-mercaptopurine, thiamiprine, thiguanine, ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone, aminoglutethimide, mitotane, trilostane, folinic acid, aceglatone, aldophosphamide glycoside, aminolevulinic acid, eniluracil, amsacrine, bestrabucil, bisantrene, edatraxate, defofamine, demecolcine, diaziquone, elfornithine, elliptinium acetate, etoglucid, gallium nitrate, hydroxyurea, lentinan, lonidainine, maytansine, ansamitocins, mitoguazone, mitoxantrone, mopidanmol, nitraerine, pentostatin, phenamet, pirarubicin, losoxantrone, 2-ethylhydrazide, procarbazine, polysaccharide-k, razoxane, rhizoxin, sizofiran, spirogermanium, tenuazonic acid, triaziquone, 2,2',2''-trichlorotriethylamine, T-2 toxin, verracurin A, roridin A, and anguidine, urethane, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, gacytosine, arabinoside, cyclophosphamide, thiotepa, paclitaxel, albumin-engineered nanoparticle formulation of paclitaxel, doxetaxel, chlorambucil, gemcitabine, 6-thioguanine, mercaptopurine, cisplatin, carboplatin, vinblastine, platinum, etoposide, ifosfamide, mitoxantrone, vincristine, vinorelbine, novantrone, teniposide, edatrexate, daunomycin, aminopterin, xeloda, ibandronate, CPT-11, topoisomerase inhibitor RFS 2000, difluoromethylornithine, retinoic acid, capecitabine, or pharmaceutically acceptable salts, solvates or acids of any of the foregoing; (b) monokine, a lymphokine, a polypeptide hormone, parathyroid hormone, thyroxine, relaxin, prorelaxin, a glycoprotein hormone, follicle stimulating hormone, thyroid stimulating hormone, luteinizing hormone, hepatic growth factor fibroblast growth factor, prolactin, placental lactogen, tumor necrosis factor-.alpha., tumor necrosis factor-.beta., mullerian-inhibiting substance, mouse gonadotropin-associated peptide, inhibin, activin, vascular endothelial growth factor, thrombopoietin, erythropoietin, an osteoinductive factor, an interferon, interferon-.alpha., interferon-.beta., interferon-.gamma., a colony stimulating factor ("CSF"), macrophage-CSF, granulocyte-macrophage-CSF, granulocyte-CSF, an interleukin ("IL"), IL-1, IL-la, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, a tumor necrosis factor, TNF-.alpha., TNF-.beta., a polypeptide factor, LIF, kit ligand, or a combination of any of the foregoing; (c) diphtheria toxin, botulium toxin, tetanus toxin, dysentery toxin, cholera toxin, amanitin, .alpha.-amanitin, pyrrolobenzodiazepine, tetrodotoxin, brevetoxin, ciguatoxin, ricin, AM toxin, auristatin, tubulysin, geldanamycin, maytansinoid, calicheamycin, daunomycin, doxorubicin, methotrexate, vindesine, SG2285, dolastatin, auristatin, cryptophycin, camptothecin, rhizoxin, CC-1065, duocarmycin, an enediyne antibiotic, esperamicin, epothilone, a toxoid, or a combination of any of the foregoing; (d) an affinity ligand, wherein the affinity ligand is a substrate, an inhibitor, a stimulating agent, a neurotransmitter, a radioisotope, or a combination of any of the foregoing; (e) a radioactive label, .sup.32P, .sup.35S, a fluorescent dye, an electron dense reagent, an enzyme, biotin, streptavidin, dioxigenin, a hapten, an immunogenic protein, a nucleic acid molecule with a sequence complementary to a target, or a combination of any of the foregoing; (f) an immunomodulatory compound, an anti-cancer agent, an anti-viral agent, an anti-bacterial agent, an anti-fungal agent, and an anti-parasitic agent, or a combination of any of the foregoing; (g) tamoxifen, raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, or toremifene; (h) 4(5)-imidazoles, aminoglutethimide, megestrol acetate, exemestane, letrozole, or anastrozole; (i) flutamide, nilutamide, bicalutamide, leuprolide, goserelin, or troxacitabine; (j) an aromatase inhibitor; (k) a protein kinase inhibitor; (l) a lipid kinase inhibitor; (m) an antisense oligonucleotide; (n) a ribozyme; (o) a vaccine; and (p) an anti-angiogenic agent.

19. The antibody-drug conjugate of claim 1, wherein the active agent is amanitin, auristatin, calicheamicin, camptothecin, cryptophycin, daunomycin, dolastatin, doxorubicin, duocarmycin, epothilone, esperamicin, geldanamycin, maytansinoid, methotrexate, monomethyl auristatin E ("MMAE"), monomethyl auristatin F ("MMAF"), pyrrolobenzodiazepine, rhizoxin, SG2285, tubulysin, vindesine, or toxoid.

20. The antibody-drug conjugate of claim 1, wherein B is: ##STR00036## ##STR00037## ##STR00038## wherein y is an integer of 1 to 10.

21. A pharmaceutical composition comprising the antibody-drug conjugate of claim 1.

22. A method of treating cancer in a subject, comprising administering the pharmaceutical composition of claim 21 to the subject.

23. The antibody-drug conjugate of claim 8, wherein the linker comprises at least one isoprenyl unit, represented by ##STR00039##

24. The antibody-drug conjugate of claim 9, wherein the linker comprises at least one isoprenyl unit, represented by ##STR00040##

25. The antibody-drug conjugate of claim 11, wherein the linker comprises at least one isoprenyl unit, represented by ##STR00041##

26. The antibody-drug conjugate of claim 1, wherein L satisfies at least one of the following (i) to (iii): (i) the alkylene includes at least one unsaturated bond, (ii) the alkylene includes at least one heteroarylene, (iii) the alkylene is substituted with one or more alkyls having 1 to 20 carbon atoms.

Details for Patent 10,118,965

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23 ⤷  Free Forever Trial LegoChem Biosciences, Inc. (Daejeon, KR) 2035-09-25 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23 ⤷  Free Forever Trial LegoChem Biosciences, Inc. (Daejeon, KR) 2035-09-25 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23 ⤷  Free Forever Trial LegoChem Biosciences, Inc. (Daejeon, KR) 2035-09-25 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23 ⤷  Free Forever Trial LegoChem Biosciences, Inc. (Daejeon, KR) 2035-09-25 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Merck
Harvard Business School
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.